Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

MorphoSys Raises EUR 84 Million in Private Placement

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
Net proceeds from the transaction will be used to fund the clinical development of MOR208.

MorphoSys AG has announced that it has raised gross proceeds of approximately EUR 84 million in a private placement via an accelerated book building procedure.

MorphoSys issued 1,514,066 new shares from authorized capital to international institutional investors at a price of EUR 55.76 per share, which corresponds to the closing auction price on 18 September 2013, one day prior to the launch of the transaction.

The offering represents approximately 6.3% of the registered pre-transaction share capital and will bring the total number of registered shares after the issuance to 25,669,444, and was multiple times over-subscribed.

The new shares will be admitted to listing on the Frankfurt Stock Exchange following their issuance.

The net proceeds from the transaction will be used by MorphoSys to:
• fund the clinical development of MOR208, our wholly owned anti-CD19 antibody, potentially including an additional phase 2 combination study in chronic lymphocytic leukemia (CLL). MOR208 has completed a phase 1 study in CLL and is in ongoing phase 2 clinical trials in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL);
• fund the further clinical development of MOR202 (an anti-CD38 antibody currently in a phase 1/2a clinical trial in multiple myeloma), for which MorphoSys has signed a global co-development agreement with Celgene;
• initiate, advance and/or accelerate the development of other proprietary programs, including advancing of pre-clinical or clinical stage assets into later stages of clinical development prior to licensing;
• fund potential acquisitions of new businesses, technologies or products, including MorphoSys's Innovation Capital initiative, that would complement our business or expand our portfolio.

"We are very pleased to announce the successful completion of our placement which we believe reflects the significant progress made at MorphoSys over the past year," said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

Dr. Moroney continued, "We have made considerable progress in advancing our pipeline and have announced ground-breaking partnerships with both GlaxoSmithKline and Celgene. The funds we have raised will allow us to further develop our wholly-owned program MOR208, to build on the great potential of MOR202 with our partner Celgene and to invest in other attractive opportunities. We believe MorphoSys is well positioned to build on this positive momentum and to continue to build significant value to shareholders."

Jens Holstein, Chief Financial Officer of MorphoSys AG commented: "In response to the progress the company achieved in recent years and the further promise of our pipeline, we received strong interest from international investors. The offering has allowed us to meet this demand, strengthen our financial position and further enhance trading liquidity. The funds raised will provide additional strategic flexibility as we continue to build the company to create long-term value for our shareholders."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gene-Edited Immune Cells Treat ‘Incurable’ Leukaemia
A new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells programmed to hunt out and kill drug resistant leukaemia has been used at Great Ormond Street Hospital (GOSH).

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos